The 9th IAS Conference on HIV Science (IAS 2017), organised by the International AIDS Society, took place in Paris, France, from 23-26 July 2017.

Conference highlights

HIV Community Forum

Watch the highlights film from the HIV Community Forum, hosted by NAM aidsmap.

Conference bulletins

Catch up on conference news with our summary bulletins. Available in English, French, Italian, Russian, Portuguese and Spanish.

Cure research

Why curing HIV may be like curing cancer – and may be as difficult.

$90-$90-$90 target

Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows.

Treatment as prevention

International study of gay couples reports no transmissions from an HIV-positive partner on treatment.


France’s next PrEP study aims to assess the wider impact of PrEP on the HIV epidemic.

HIV testing

Can self-testing engage 'hard-to-reach' men with HIV testing?

Treatment as prevention

Swaziland: new infections halved in five years as HIV treatment scales up.

90-90-90 target

World on track to reach the 90-90-90 targets for HIV treatment by 2020.

aidsmap news from IAS 2017

← First123Next →

Editors' picks from other sources

Email bulletins

Sign up for our news bulletins

Find out more and sign up to the full range of aidsmap email bulletins >

Official conference website

Find out more about the conference and view the programme on the official conference website.

Visit the conference website >

aidsmap news apps

Keep up to date with the latest HIV news using the free aidsmap news apps for android and iPhone.

Download the app >

NAM's news coverage of the International AIDS Society's Conference on HIV Science has been made possible thanks to support from Gilead Sciences Europe Ltd. and Merck & Co. NAM's wider conference news reporting services have been supported by Janssen and ViiV Healthcare.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.